ProKidney Corp. (PROK)
 NASDAQ: PROK · Real-Time Price · USD
 3.080
 -0.020 (-0.65%)
  Oct 30, 2025, 4:00 PM EDT - Market closed
ProKidney Revenue
ProKidney had revenue of $221.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $527.00K. In the year 2024, ProKidney had annual revenue of $76.00K.
Revenue (ttm) 
 $527.00K
Revenue Growth 
 n/a
P/S Ratio 
 1,725.66
Revenue / Employee 
 $2,583
Employees 
 204
Market Cap 
909.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 76.00K | - | - | 
| Dec 31, 2023 | - | - | - | 
| Dec 31, 2022 | - | - | - | 
| Dec 31, 2021 | - | - | - | 
| Dec 31, 2020 | - | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| Eli Lilly and Company | 59.42B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
PROK News
- 1 day ago - ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference - GlobeNewsWire
- 10 days ago - ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025 - GlobeNewsWire
- 5 weeks ago - ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy - Seeking Alpha
- 7 weeks ago - ProKidney Corp. (PROK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 2 months ago - ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 2 months ago - ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates - GlobeNewsWire
- 3 months ago - ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel - GlobeNewsWire